Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 9/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | PREP | P48147 | 1/20 | 0.34 |
| ▸ | FAP | Q12884 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6049711 | 0.79 | P2RX7 (0.53) | P2RX7 | |
| SCHEMBL7600625 | 0.78 | MEN1 (0.48) | P2RX7MEN1KMT2ACHRM1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5960226 | 0.78 | P2RX7 (0.52) | P2RX7 | |
| SCHEMBL5080702 | 0.78 | P2RX7 (0.67) | P2RX7 | |
| SCHEMBL7555457 | 0.78 | P2RX7 (0.47) | P2RX7MEN1KMT2ACHRM1CA1 | |
| SCHEMBL5398913 | 0.77 | P2RX7 (0.63) | P2RX7MEN1KMT2ACHRM1SMN1; SMN2 | |
| SCHEMBL7552675 | 0.76 | P2RX7 (0.41) | P2RX7MEN1KMT2ACHRM1 | |
| SCHEMBL7603269 | 0.76 | P2RX7 (0.45) | P2RX7MEN1KMT2ACHRM1SMN1; SMN2 | |
| SCHEMBL8081000 | 0.75 | CA1 (0.55) | P2RX7MEN1KMT2ALMNATP53 | |
| SCHEMBL7559952 | 0.74 | P2RX7 (0.61) | P2RX7MEN1KMT2ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007505900-A | — | — | 2007-03-15 | — | — | JP | claimed |
| JP-2007501270-A | — | — | 2007-01-25 | — | — | JP | claimed |
| EP-1663224-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING A P2X7 RECEPTOR ANTAGONIST AND A NONSTEROIDAL ANTI INFLAMMATORY DRUG | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | claimed |
| EP-1644042-A1 | A PHARMACEUTICAL COMPOSITION CONTAINING A P2X7 RECEPTOR ANTAGONIST AND METHOTREXATE | AstraZeneca AB (SE) | 2006-04-12 | — | — | EP | claimed |
| EP-1644041-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING A P2X7 ANTAGONIST AND SULFASALAZINE | AstraZeneca AB (SE) | 2006-04-12 | — | — | EP | claimed |
| EP-1633401-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING A P2X7-RECEPTOR ANTAGONIST AND A TUMOUR NECROSIS FACTOR ALPHA | AstraZeneca AB (SE) | 2006-03-15 | — | — | EP | claimed |
| WO-2005025571-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING A P2X7 RECEPTOR ANTAGONIST AND A NONSTEROIDAL ANTI INFLAMMATORY DRUG. | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | claimed |
| WO-2004105796-A1 | A PHARMACEUTICAL COMPOSITION CONTAINING A P2X7 RECEPTOR ANTAGONIST AND METHOTREXATE | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | WO | claimed |
| WO-2004105797-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING A P2X7 ANTAGONIST AND SULFASALAZINE | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | WO | claimed |
| WO-2004105798-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING A P2X7-RECEPTOR ANTAGONIST AND A TUMOUR NECROSIS FACTOR α | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | WO | claimed |
| EP-3402469-A1 | P2X7 RECEPTOR ANTAGONISTS FOR RESTORING T-CELL LYMPHOPOIESIS IN SUBJECTS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) | Institut National de la Sante et de la Recherche Medicale (INSERM) (FR) | 2018-11-21 | — | — | EP | disclosed |
| WO-2017121840-A1 | P2X7 RECEPTOR ANTAGONISTS FOR RESTORING T-CELL LYMPHOPOIESIS IN SUBJECTS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-07-20 | — | — | WO | disclosed |
| EP-1663224-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING A P2X7 RECEPTOR ANTAGONIST AND A NONSTEROIDAL ANTI INFLAMMATORY DRUG | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | disclosed |
| EP-1644042-A1 | A PHARMACEUTICAL COMPOSITION CONTAINING A P2X7 RECEPTOR ANTAGONIST AND METHOTREXATE | AstraZeneca AB (SE) | 2006-04-12 | — | — | EP | disclosed |
| EP-1644041-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING A P2X7 ANTAGONIST AND SULFASALAZINE | AstraZeneca AB (SE) | 2006-04-12 | — | — | EP | disclosed |
| EP-1633401-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING A P2X7-RECEPTOR ANTAGONIST AND A TUMOUR NECROSIS FACTOR ALPHA | AstraZeneca AB (SE) | 2006-03-15 | — | — | EP | disclosed |
| WO-2005025571-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING A P2X7 RECEPTOR ANTAGONIST AND A NONSTEROIDAL ANTI INFLAMMATORY DRUG. | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |
| WO-2004105796-A1 | A PHARMACEUTICAL COMPOSITION CONTAINING A P2X7 RECEPTOR ANTAGONIST AND METHOTREXATE | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004105797-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING A P2X7 ANTAGONIST AND SULFASALAZINE | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004105798-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING A P2X7-RECEPTOR ANTAGONIST AND A TUMOUR NECROSIS FACTOR α | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | WO | disclosed |